Yung Lyou, MD, PhD, discusses the efficacy of androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Yung Lyou, MD, PhD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the efficacy of androgen-deprivation therapy (ADT) plus docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Results from the phase 3 CHAARTED trial (NCT00309985), which examined ADT with or without docetaxel in this patient population, demonstrated that the combination improved overall survival (OS) compared with ADT alone, according to Lyou. Additionally, for patients with high-volume disease, defined as those with at least 4 metastatic lesions in the bones or more than 1 visceral metastasis, the median OS was 51.2 months with the combination vs 34.4 months with ADT alone, demonstrating a clear benefit to adding docetaxel, Lyou explains.
However, docetaxel has been associated with adverse effects, such as peripheral neuropathy and myelosuppression, Lyou adds. Overall, the study found that the combination was most beneficial for patients with high-volume disease, with no significant difference in OS observed in those with low-volume disease, Lyou concludes.